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Figure: Hemodynamic data before(baseline), during (8, 24, and 72 hrs) and after (24
hrs) treatment with CRS. * = p< 0.05 vs Baseline.
1088-124 Pletal in Lieu of Home Parenteral Inotropes
Marc R. Pritzker, Rhonda Groebner, Duand Burns, Casey Lawler, Maria T. Olivari, 
Minneapolis Heart Institute Foundation, Minneapolis, MN, University of Minnesota, 
Minneapolis, MN
Despite successful treatment with poly drug regimens for heart failure, some patients
cannot be discharged from the hospital because of persistent symptoms or complications
of heart failure. In order to facilitate home discharge we offered twelve patients with ino-
trope dependent failure, discharge on Pletal, an oral phosphosdiesterase inhibitor similar
to Milrinone. Reasons for inotrope dependence included: limiting symptoms of low car-
diac output, hyperkalemia, cognitive dysfunction, renal insufficiency, recurrent pleural
effusions. All patients were informed of their prognosis as well as the previously noted
increased risk of sudden death associated with continuous inotrope administration.
Eleven of 12 patients had previously placed AICDs. All patients were on optimal dosages
of carvedilol (mean 37.5 mgs/day). Pletal dosage was 100 mgs BID. Two elderly patients
died at home, per their desire, within 3 weeks of discharge. Neither death appeared to be
associated with tachyarrhythmia. In late survivors (mean 16months, range 3-22months)
there have been two late deaths at 3 and 22 months associated with sudden death and
malignancy respectively. No patient has required re-hospitalization. Appropriate AICD
device discharges have occurred in 3 patients, 1 spontaneous, 1 hypokalemia related
and 1 associated with increased Pletal dosage. All patients are able to perform activities
of daily living, socialize and shop outside the home, and feel that the risk of sudden death
is acceptably counterbalanced by improvements in quality of life. Oral Pletal therapy
appears to facilitate hospital discharge, reduce readmission, and allows for an acceptable
quality of life outside the hospital.
1088-125 Levosimendan Is Safe and Effective in Patients With 
Severe Low Cardiac Output Heart Failure and Critical 
Hypotension
Fatima Franco, Pedro Monteiro, Joana Correia, Carla Roque, Francisco Gonçalves, 
Graça Castro, Lino Gonçalves, Mário Freitas, Luís A. Providência, Coimbra University 
Hospital, Coimbra, Portugal
Background: Management of decompensated advanced heart failure, severe hypoten-
sion, and progressive cardiogenic shock requires immediate inotropic therapy to restore
cardiac output (CO) and blood pressure (BP). Levosimendan (levo) is effective in heart
failure patients with low CO but relatively preserved BP. However, it is unknown if levo is
effective when CO and BP pressure are both critically low.
Methods: Fifteen patients (64 + 18 years; LVEF 21 + 3%) admitted to ICU due to decom-
pensated chronic heart failure with critical hypotension and progressive cardiogenic
shock, treated with medium-high doses of dobutamine (dob) and dopamine (dop) upon
arrival, were given 0.1 mcg/kg/min levo in the first 24 hours after admission to ICU
(Group 1). Clinical and hemodynamic improvement at 48 h after treatment, in-hospital
mortality, and length of hospital and ICU stay were compared to 11 patients (59 + 18
years; LVEF 20 + 3%), with the same baseline characteristics, treated with dob and dop
(Group 2).
Results: Dob/dop were weaned at 62 + 38 hours in Group 1 and at 120 + 48 hours in
Group 2 (P< 0.002). Hospital length of stay (LOS) was 14 + 5 days in Group 1 and 22 + 8
days in Group 2 (P< 0.01). ICU LOS was 5 + 3 days in Group 1 and 9 + 5 days in Group
2 (P< 0.05).
Conclusion: Our preliminary data suggest that introducing levo to conventional therapy
at early stages of treating patients with severe heart failure and cardiogenic shock
improves hemodynamic recovery and hospital outcomes compared to traditional inter-
vention. 
* Mean + SD; †P < 0.05.
1088-126 Nesiritide Does Not Improve Renal Function in Patients 
With Chronic Heart Failure and Worsening Creatinine
David J. Wang, Thomas C. Dowling, Thomas Ayala, Joanne Marshall, Stacey Minshall, 
Nancy Greenberg, Emil Thattassery, Stephen S. Gottlieb, University of Maryland School 
of Medicine, Baltimore, MD
Background: Decompensated heart failure (CHF) is often associated with worsening
renal function, a condition which limits therapeutic options. We characterized the effects
of nesiritide on renal function in these high-risk patients with the greatest need for an
intervention which improves kidney function.
Methods: In this randomized, double-blind, placebo controlled, cross-over study, 15
patients admitted for worsening heart failure, ejection fraction < 40%, & creatinine > 0.2
mg/dl over baseline were given 24 hour infusions of nesiritide (2 µg/kg bolus then .01 µg/
kg/min) or placebo during randomized consecutive 24 hour periods. Blood & urine sam-
ples were obtained and urine output recorded at hours 3, 6, 21, & 24 for each period.
Glomerular filtration rate (GFR, by iothalamate), renal plasma flow (RPF, by PAH), urine
output, and sodium excretion were measured for each time point. Diuretics & vasoactive
drugs were held for 6 hours each day.
Results: There was no effect of nesiritide on urine output, sodium excretion, GFR, or
RPF. 
Conclusion: In this population of patients with acute exacerbation of CHF and worsen-
ing renal function, nesiritide infusion exerted no significant impact on urine output, GFR,
RPF, or sodium excretion as compared to placebo. While previous studies with higher
doses of nesiritide have demonstrated increased sodium excretion and/or urine output,
the present study suggests that these effects are not present with lower doses of nesirit-
ide in patients with worsening renal function.
Clinical parameter*/ Outcome Group 1
Levo, Dob/Dop
(n=15)
Group 2
Dob/Dop
(n=11)
Baseline 48 h Baseline 48 h
Systolic BP
(mmHg)
75 + 9 91 + 8 † 77 + 6 93 + 7.8
Heart Rate
(beats/min)
106 + 16 100 + 12 † 103 + 20 107 + 16
Diuresis
(mL/hr)
22 + 20 242 + 159 † 30 + 27 114 + 112 †
Creatinine
(mg/dL)
3.3 + 1.7 2.3 + 1.6† 1.5 + 0.7 2.8 + 2.4
In-hospital
mortality (%)
27 64
0-3 Hours 3-6 Hours 6-21 Hours 21-24 Hours 24 Hour Total.
GFR (ml/min)
placebo 43.4 ± 31.4 48.5 ± 30.3 41.4 ± 27.9 44.9 ± 27.9 43.1 ± 27.0
active 41.7 ± 31.1 42.5 ± 24.8 44.3 ± 30.0 38.2 ± 21.3 43.2 ± 27.2
RPF (ml/min)
placebo 130 ± 81.5 155 ± 74.9 156 ± 80.2 182 ± 109 160 ± 70.6
active 113 ± 55.5 121 ± 55.4 153 ± 88.3 127 ± 63.2 145 ± 69.9
Urine output (ml)
placebo 217 ± 93 226 ± 157 1988 ± 939 306 ± 305 2717 ± 1231
active 206 ± 97 268 ± 227 1877 ± 1077 263 ± 230 2634 ± 1349
Na Excretion (mmol/hr)
placebo 5.19 ± 5.59 4.54 ± 5.27 9.94 ± 8.17 7.05 ± 12.9 8.51 ± 7.53
active 3.60 ± 2.55 5.70 ± 7.96 9.78 ± 8.59 7.27 ± 9.94 8.30 ± 6.67
all values: mean ± S.D.
